Literature DB >> 32439086

The Case for High-Quality Colonoscopy Remaining a Premier Colorectal Cancer Screening Strategy in the United States.

Douglas K Rex1.   

Abstract

Most colorectal cancer screening in the United States occurs in the opportunistic setting, where screening is initiated by a patient-provider interaction. Colonoscopy provides the longest-interval protection, and high-quality colonoscopy is ideally suited to the opportunistic setting. Both detection and colonoscopic resection have improved as a result of intense scientific investigation. Further improvements in detection are expected with the introduction of artificial intelligence programs into colonoscopy platforms. We may expect recommended intervals or colonoscopy after negative examinations performed by high-quality detectors to expand beyond 10 years. Thus, high-quality colonoscopy remains an excellent approach to colorectal cancer screening in the opportunistic setting.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colonoscopy; Colorectal adenomas; Colorectal cancer; Colorectal cancer screening; Colorectal polyps

Mesh:

Year:  2020        PMID: 32439086     DOI: 10.1016/j.giec.2020.02.006

Source DB:  PubMed          Journal:  Gastrointest Endosc Clin N Am        ISSN: 1052-5157


  2 in total

Review 1.  Electrochemical biosensors for measurement of colorectal cancer biomarkers.

Authors:  Wenxian Zhang; Guangchun Xiao; Jun Chen; Li Wang; Qiongzheng Hu; Jian Wu; Wenhong Zhang; Ming Song; Jinwei Qiao; Chonghai Xu
Journal:  Anal Bioanal Chem       Date:  2021-03-05       Impact factor: 4.142

2.  Longitudinal assessment of colonoscopy adverse events in the prospective Cooperative Studies Program no. 380 colorectal cancer screening and surveillance cohort.

Authors:  Elizabeth A Kobe; Brian A Sullivan; Xuejun Qin; Thomas S Redding; Elizabeth R Hauser; Ashton N Madison; Cameron Miller; Jimmy T Efird; Ziad F Gellad; David Weiss; Kellie J Sims; Christina D Williams; David A Lieberman; Dawn Provenzale
Journal:  Gastrointest Endosc       Date:  2022-05-07       Impact factor: 10.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.